La Trobe

File(s) stored somewhere else

Please note: Linked content is NOT stored on La Trobe and we can't guarantee its availability, quality, security or accept any liability.

Pembrolizumab in relapsed or refractory Richter syndrome

journal contribution
posted on 18.12.2020, 04:07 by P Armand, N Murawski, D Molin, J Zain, B Eichhorst, Z Gulbas, Eliza Hawkes, JM Pagel, T Phillips, V Ribrag, J Svoboda, A Stathis, A Chatterjee, R Orlowski, P Marinello, B Christian
No description supplied

Funding

The authors thank the patients and their families, as well as investigators and site personnel. Medical writing and/or editorial assistance was provided by Cathy R. Winter, PhD, and Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

History

Publication Date

01/07/2020

Journal

British Journal of Haematology

Volume

190

Issue

2

Pagination

4p. (p. e117-e120)

Publisher

Wiley

ISSN

0007-1048

Rights Statement

The Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.

Exports